SIGA Q1 2024: product sales $23.9M, net income $10.3M, $0.60 special dividend

SIGA TECHNOLOGIES INC

2024-Q1 EPS reported $0.14 revenue$25,429,855

Product sales $23.9M vs $5.7M YoY; total revenues $25.4M vs $8.3M.
Operating income $11.3M vs loss $2.1M YoY; net income $10.3M vs loss $0.9M; diluted EPS $0.14 vs ($0.01).
Partner Japan Biotechno Pharma filed NDA for tecovirimat in Japan for smallpox, mpox, etc. on April 11, 2024.
Amendment to Meridian agreement: SIGA takes over international promotion of oral TPOXX effective June 1, 2024.
Special cash dividend of $0.60 per share declared March 12, paid April 11, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SIGA TECHNOLOGIES INC reported three months ended March 31, 2024 results: revenue $ 25.4, net income $ 10.3, EPS $ 0.14.

Period: three months ended March 31, 2024
Revenue: $ 25.4
Net income: $ 10.3
EPS: $ 0.14
Result: reported results

Exact text from the filing

Summary Financial Results ($ in millions, except per share amounts) Three Months Ended March 31 2024 2023 Product sales (1) $ 23.9 $ 5.7 Total revenues $ 25.4 $ 8.3 Operating income (loss) (2) $ 11.3 $ (2.1 ) Income (loss) before income taxes (2) $ 13.2 $ (1.2 ) Net income (loss) $ 10.3 $ (0.9 ) Diluted income (loss) per share $ 0.14 $ (0.01 )

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

SIGA TECHNOLOGIES INC filing history →

Source: SEC EDGAR

accession 0001140361-24-024697

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.